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Abstract
Purpose of Review Islet transplantation, an important approach to achieve insulin independence for individuals with type 1
diabetes, is limited by the lack of accurate biomarkers to track beta-cell death post islet infusion. In this review, we will discuss
existing and recently described biomarkers.
Recent Findings As beta cells are killed by the immune system, fragments of beta cell-specific cell-free DNA and proteins are
released into the periphery. Several different strategies to identify these fragments have been described. Some circulating, non-
coding microRNAs, particularly miRNA-375 are also showing potential to reflect the rate of beta cell loss post-clinical islet
transplantation.
Summary Recent advances in identifying accurate beta cell-specific biomarkers such as differentially methylated insulin cell-free
DNA and circulating miRNA-375 may help predict clinical outcomes. More studies are required to examine the robustness of
these biomarkers to detect chronic beta-cell loss in islet transplantation recipients.
Keywords Biomarker . Type 1 diabetes . Cell-free DNA .microRNA375 . Islet transplantation
Introduction
Type 1 diabetes (T1D) is a chronic autoimmune disease that
results from specific immune-mediated destruction of the
insulin-producing beta cells in the pancreatic islets of
Langerhans. Uncontrolled hyperglycemia characterises this
autoimmune disorder, due to insufficient insulin production.
Although not the most common form of diabetes (accounting
for approximately 10% of all diabetes), T1D is the most com-
mon form of diabetes among children and adolescents under
the age of 20 [1]. According to the most recent report from the
International Diabetes Federation (IDF) in 2017, the incidence
rate of T1D is increasing by 3% annually with approximately
132,600 new cases registered each year. There are about 1.1
million children and adolescents under the age of 20 years
living with the condition globally, half of whom live either
in Europe (28.4%) or North American/Caribbean regions
(21.5%). Prediction studies from EURODIAB-registered chil-
dren revealed that the incidence of T1D is projected to double
in European children diagnosed under the age of 5 years be-
tween the years 2005 and 2020, and T1D prevalence will
increase up to 70% in children under age 15 years [2].
Additionally, analysis of time trends by the Nationwide
Diabetes Incidence Study in Sweden (DISS) [3] showed that
the incidence of T1D onset in individuals aged 0–34 years
from 1983 to 2007 is shifting to younger ages [4]. Taken
together, these data suggest a growing population of young
people with T1D. Clinical symptoms such as thirst, frequent
urination and fatigue [1] appear when approximately 70–80%
of an individual’s beta cells have been destroyed [5, 6]. At this
point, the only option for the patient is lifelong insulin replace-
ment and blood glucose monitoring. Insulin replacement does
not work equally for all recipients. Exogenous insulin is not as
exquisite as native insulin in controlling blood sugar levels,
and the Diabetes Control and Complications Trial (DCCT)
showed that there is an association between glucose
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homeostasis and the risk of developing chronic T1D micro
and macrovascular complications [7, 8] highlighting the im-
portance of good blood glucose control.
The Pancreatic Beta Cell
The beta cell is a hormone-secreting cell that forms a signifi-
cant component of the islets of Langerhans in the pancreas
(approximately 60–80%) [9]. In addition to beta cells, the
islets contain four types of endocrine hormone-producing
cells: 30% alpha cells (secreting glucagon), < 10% delta cells
(secreting somatostatin), < 5% gamma cells (secreting pancre-
atic polypeptide) and epsilon cells (secreting ghrelin) [9–13].
The islets compose the endocrine pancreas and account for
only 1–2% of the total mass of the human pancreas [9].
Anatomical and three-dimensional (3D) visualisation showed
that the endocrine pancreas is uniquely heterogeneous with
regard to islet number and size. The total number of islets
range between 3.6 and 14.8 million, and their volume varies
from 0.5 to 1.3 cm3 [9, 14–16]. The total number of islets is
highest in the body/tail of the pancreas [9].
T1D Reversal Strategies
Currently, the primary approach to attempt to cure T1D is by
restoring beta-cell mass and controlling the ongoing autoim-
mune reaction. To date, there are two clinically available
methods for restoring beta cell mass; the first is whole pancre-
as transplantation; the second is through transplantation of
only the islets of Langerhans, both of which are usually har-
vested from brainstem death donors. These methods of beta-
cell replacement are therefore only offered to patients with
ongoing difficulties in controlling their blood glucose levels
through insulin management [17]. According to the interna-
tional pancreas transplant registry, the overall survival rates
among their Pancreas After Islet (PAI) transplantation recipi-
ents (n = 40) were 97%, 1- year post-transplantation, and 83%,
5-year post-transplantation [18]. The registry reported that the
current patient survival rate at 3-year post-transplantation is
more than 93% with graft function in the simultaneous pan-
creas and kidney recipient greater than 83% and solitary pan-
creas graft > 70% [19•]. Nevertheless, the process involves
major surgery, prolonged hospitalisation and the need for
life-long immunosuppressive therapy [18].
Enhanced Islet Transplantation
Protocol–Edmonton Protocol
Unlike whole pancreas transplantation, islet transplantation is
a non-invasive strategy to treat T1D, as it does not require
major surgery or prolonged hospitalisation; the patient will,
however, require ongoing immunosuppressive medication. A
multicentre, randomised controlled trial by the TRIMECO
study group compared the efficiency of islet transplantation
to the intensive insulin treatment in patients with severe
hypoglycaemia or hypoglycaemia unawareness. The results
showed that 84% (21 of 25) of islet transplantation recipients
had restored normoglycemic levels 6-month post-islet trans-
plantation, while 0% of patients who received intensive insu-
lin attained such enhancement. The trial also showed that 59%
of islet graft recipients (27 of 46) achieved insulin indepen-
dence 1-year post-transplantation [20].
Clinical islet transplantation is primarily performed by in-
fusing self or donated islets into the patient’s portal vein from
where the islets are distributed throughout the liver. An inno-
vative immunosuppressive treatment and cautious preparation
of islets allowed the researchers at the University of Alberta
(Edmonton, Canada) to achieve complete insulin dependence
for seven patients with T1D, 1-year post-islet transplantation
[21]. The “Edmonton Protocol” used an immunosuppressive
combination of glucocorticoid-free drugs comprising
sirolimus, tacrolimus and daclizumab as well as enhanced
methods of islet isolation, with an emphasis on transplanting
a sufficient number of islets for the recipient. The recommend-
ed islet mass for infusion is 5–7000 islet equivalents (IEQ)/kg
of recipient’s body weight from two or more donated
pancreases [22, 23]. The Phase 3 Trial of the Clinical Islet
Transplantation Consortium (CIT-07) had registered 48 T1D
patients (T1D duration > 5 years) in eight islet transplantation
centres who underwent islet engraftment. Their report showed
that 87.5% of the registered patients achieved normal glucose
levels (HbA1c > 7%) 1-year post the first islet infusion and
71% remained normoglycemic two years later [24•, 25].
According to the Collaborative Islet Transplant Registry,
more than 1500 patients have received islet transplantation
worldwide [22]. Advances in donor selection, islet isolation
and enhanced immunosuppression regimes have resulted in
long-term insulin independence in more than 50% of clinical
islet transplantation recipients mirroring the outcomes of the
whole-organ pancreas transplantation in selected international
centres [22, 26]. It is also worth highlighting here that more
studies are required to optimise immunosuppression strategies
as the majority of adverse events associated with the islet
transplantation procedure originated from immunosuppres-
sion medications [20].
Monitoring Graft Outcomes
Despite the encouraging outcomes from islet transplantation
on enhancing the quality of life of patients with T1D who
previously had difficulties controlling blood glucose levels,
in general, however, islet function decreases over time in islet
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transplant recipients and repeat transplants are required. The
procedure can be negatively impacted by significant cell loss
during and immediately after islet infusion due to instant
blood-mediated inflammatory responses, cell metabolic ex-
haustion and hypoxia [27–29]. Long-term, the clinical out-
come is hampered by a recurrence of islet autoimmunity and
rejection. Efforts to improve the outcome include strategies to
increase islet engraftment and to protect transplanted islets
from the host immune system. Biomarkers are crucial to mon-
itor ongoing graft function, but no validated direct measure
exists to reliably monitor the rate of engrafted cell death, and
this is a limitation of the procedure.
Currently, clinical islet transplantation relies on the meta-
bolic biomarkers such as the levels of blood glucose,
haemoglobin A1C (HbA1C), stimulated C-peptide and daily
insulin measurement to assess the function of the graft [30].
Although it is not affected by exogenous insulin, C-peptide
measurement has several limitations as an indicator of trans-
plant rejection; it is influenced by factors that have impact
insulin secretion, such as insulin resistance [31]. Further, it is
well established that C-peptide often fails to reflect the pres-
ence of beta-cell destruction during the earlier pre-diabetic
stage and therefore is only useful for gross changes in beta-
cell function. The ability to measure subtle changes in the rate
of beta-cell death in islet transplant recipients would inform
clinical interventions.
Autoantibodies to the islet antigens insulin (IAA), glutamic
acid decarboxylase (GADA), islet cell antigen-2 (IA-2A) and
zinc transporter 8 (ZnT8A) are unsurpassed as biomarkers to
predict future T1D but their use as biomarkers in islet trans-
plantation has been less definitive. Increases in autoantibody
level with epitope spreading were associated with an adverse
outcome [32], but this has not been reported by all centres, so
long-term follow-up with harmonised islet autoantibody as-
says is required to establish the predictive capacity of islet
autoantibody level and characteristics in the islet transplanta-
tion setting.
Alloimmunity is monitored throughmeasurement of donor-
specific autoantibodies (DSA) against donor HLA antigens
but results from studies to date have proved confusing. DSA
positivity before transplantation has been associated with graft
failure [33, 34], but not by all studies [32, 35] while the study
of the appearance of DSA post-transplant has also proven con-
troversial [32, 33, 36–39]. As with islet autoantibody analysis,
further collaborative studies are required to understand the true
potential usefulness of DSA in islet transplantation. The lack
of current real-time biomarkers to measure the efficacy of pre-
ventative and interventional therapeutic approaches still poses
an immense challenge in islet transplantation. Recently, evi-
dence has accumulated showing that biomarkers such as
microRNA and differentially methylated cell-free DNA of
key beta cell genes have the potential to be powerful tools to
evaluate transplantation success and graft function.
A biomarker is an indicator that objectively measures a
normal or pathological state as well as evaluating biological
responses to a therapeutic intervention [40]. Ideally, a bio-
marker should have some specific criteria to be of clinical
value; it should be with highly selective and specific to a
target, stable, unaffected by physiological or metabolic chang-
es, have a detectable threshold in the circulation and be repro-
ducible. Above all, a biomarker should be non-invasive, ac-
ceptable to the patient and easily interpreted by the clinician
(Table 1) [41]. Furthermore, an acceptable biomarker should
apply to different populations, have a series of cut-off values
in a general population and be detectable in the early stage of
the disease. Extra considerations should be weighed up for
diagnostic and therapeutic biomarkers: the expense, the diffi-
culty of sample collection and the patient disturbance during
sample collection. For example, a biomarker destined to be
used in routine screening tests should have the advantage of
both easy access from patients and minimum cost per sample.
On the other hand, diagnostic and research study biomarkers
should be highly specific for the target specimen such as a
tissue biopsy. In that case, the number of samples processed
will be limited, but the specificity and the sensitivity will be at
their maximum [41].
Circulating Proteins in Assessing
the Outcomes of Clinical Islet Transplantation
Glutamic acid decarboxylase 65 (GAD65) was one of the first
candidate biomarkers to be suggested for detection of beta cell
death in models of diabetes [42, 43]. A preclinical report
studying the level of variant biomarkers for monitoring beta
cell death post auto- and allo-islet graft into dogs had reported
that enzymatic assay for GAD achieved limited success in
predicting of islet graft rejection; nevertheless, the authors
Table 1 Features and characterisation of the ideal biomarker
Characterisation Comments
Specific Have the ability to differentiate pathological from
normal state
Specific to the affected cells or tissue
Sensitive Rapid and Significant release upon disease
development
Anticipative Long half-life in biological sample
Its release is proportional to the degree disease severity
Robust Rapid, simple, accurate and inexpensive detection
Not changed by environmental factors and other
diseases
Non-invasive Present in easy accessible biological fluid samples
Minimum risk to the patient at the time of sample
collection
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were optimistic about the possibility of detection of islet-
specific proteins during preclinical stage of the diabetes
[44]. Human GAD65 is reported to be expressed in neuro-
endocrine cell types, brain and pancreatic alpha, beta and
delta cells [42]. In patients receiving an intraportal islet
allotransplant elevated GAD65 was detected within hours
of surgery, but more sensitive assays are required to detect
more subtle episodes of cell death that may inform graft
rejection or recurrent diabetes [45].
The development of more sensitive detection methods,
such as time-resolved fluorescent immunoassay technologies
(TRFIA) [46] have shown some promise for predicting the
outcomes of clinical islet transplantation, but it was insuffi-
cient to consistently detect GAD65 in all recipients [45, 47].
More recently, development of advanced immunoassay plat-
forms such as the Cytometric Bead Array (CBA), the
ElectroChemiLuminescence ImmunoAssay (ECLIA) and
the digital ELISA technology (Single Molecule Array-
SIMOA) had improved the sensitivity of the assay for de-
tecting circulating GAD65 in the sup-picomolar range
[48]. More studies are required, however, to test the utility
of these advanced technologies in measuring beta cell
death and predicting future outcomes in islet transplanta-
tion recipients. In addition, one concern is that the use of
GAD65 as a biomarker might be limited by the presence of
circulating GAD65 autoantibodies in the periphery of T1D
islet recipients.
MicroRNA in Assessing the Outcomes
of Clinical Islet Transplantation
MicroRNAs have multiple distinctive features, and provid-
ing that they are genuinely tissue-specific, they could be
potentially powerful biomarkers for evaluating changes in
health and disease. MicroRNAs are abundant in multiple
easy-to-collect biological samples such as urine, saliva,
tears, seminal fluid and breast milk [49]. Moreover, previ-
ous studies showed that microRNA levels are amenable to
measurement using different methodologies [50–55].
Accumulating data emphasise a role for circulating
microRNAs (miR) in controlling the physiological path-
ways of insulin secretion and beta-cell survival [56].
miR-375 was one of the first identified, most abundant
islet-specific microRNAs and also one of the best-
characterised microRNAs regarding its function [57].
NeuroD1/BETA2 and PDX-1 both synergistically control
the expression of miR-375 [58]. miR-375 plays a funda-
mental role in normal glucose homeostasis, alpha- and
beta-cell turnover, and adaptive beta-cell expansion in re-
sponse to increasing insulin demand in insulin resistance
[57, 59, 60]. Measuring the level of miR-375 to monitor
beta cell death has been described previously [61–63]
when the absolute and relative levels of miRNA-375 were
associated with the level of beta cell damage in vivo and in
vitro [64]. Piemonti and colleagues had previously sug-
gested that circulating miR-375 levels could potentially
be a non-invasive biomarker for monitoring beta cell death
post-islet transplantation. A total of 22 human islet infu-
sions were studied under different immunosuppression
treatments. They reported that serum miR-375 had upreg-
ulated 200-fold within the first 12 h of infusion, and then
decreased to baseline level 24 h post-infusion. A second
peak was reported at 96 h preceded by elevated C-reactive
protein and cross-linked fibrin degradation products, and
followed by an increase in the cell damage markers aspartate
aminotransferase, alanine aminotransferase and lactate dehy-
drogenase [65]. Subsequently, the Naziruddin group also stud-
ied the level of miR-375 in patients undergoing pancreatecto-
my with islet autologous or allogeneic transplantation (n =
29). They showed that miR-375 was significantly elevated
within 3 h post-infusion. Additionally, they demonstrated that
the rising level of miR-375 mirrored the rising level of C-
peptide post-islet infusion [64]. Later, the same group was
able to confirm their previous conclusion showing that miR-
375 was a reliable indicator for predicting islet death post-
transplantation. Following up a total pancreatectomywith islet
autotransplantation (TPIAT) patients for 1-year post-trans-
plantation (n = 31) revealed that miR-200c correlates with
the islet metabolic transplantation outcomes. The data showed
that high relative miR-200c expression (< 1.5) was associated
with a favourable engraftment function and with less insulin
dependence [66]. These early observations need to be follow-
ed up with large longitudinal studies.
DNA Methylation in Assessing the Outcomes
of Clinical Islet Transplantation
Differentially methylated DNA-based biomarkers of beta cell-
specific genes have been reported to correlate with the rate of
beta-cell death in recently diagnosed T1D, those who are at
risk for developing the disorder and assessing the outcomes of
novel clinical therapies [67–71, 72••, 73, 74••]. Dying beta
cells during the pathology of T1D release their DNA content
into the circulation. There are some specific cytosines within
this DNA that have a differential methylation pattern that al-
lows the cell of origin of the DNA to be identified. These
uniquemethylation signatures are mainly within the genes that
are vital for cell function and identity maintenance. As shown
in Fig. 1, well-established methodologies exist to identify the
differentially methylated sites. To date, studies that employed
differentially methylated DNA-based biomarkers to assess the
outcomes of islet transplantation have focused on the beta-
cell-specific insulin gene (INS) (Table 2). Husseiny and
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colleagues in 2014 followed up islet transplant patients (n = 6)
and showed that beta cell-specific hypomethylated INS cell-
free DNA (cfDNA) was significantly increased a day after
transplantation; according to their data, the elevated level per-
sists for at least 14 days post the infusion [70]. Differentially
hypomethylated CpG sites within the INS promoter were also
used to interpret the outcomes of allogeneic islet transplanta-
tion in longstanding T1D patients by Lehmann-Werman and
colleagues [72••]. They showed that beta cell-specific cfDNA
was detected in the plasma of islet recipients 1–2 h post-
infusion; the level declined sharply in the following hours
and days in a manner that was in parallel with the result seen
previously in imaging studies on islet transplantation recipi-
ents [76]. More recently, another group using the same ap-
proach used by Lehmann-Werman observed a correlation be-
tween beta cell-specific cfDNA levels post-clinical islet allo-
graft at a specific time point and the graft outcomes [75••].
They reported that there were two waves of high beta cell-
specific cfDNA signals in their islet graft recipients (n = 37);
the first was a temporary and a highly intense signal seen
Fig. 1 Sodium bisulfite conversion of genomic DNA. This allows
methylated and unmethylated residues to be discriminated. a The
conversion occurs on denatured, single-stranded DNA with sodium
bisulfite at high temperature and low pH (pH = 5). The reaction starts
when the unmethylated 6th carbon atom of the cytosine is sulfonated,
then, irreversible hydrolytic deamination occurs at the 4th carbon atom
that converts the molecule into uracil sulfonate, and, finally, a succeeding
desulfonation occurs in an alkaline environment converting the molecule
into a uracil nucleotide. The cytosine methylation at 5th carbon atom
obstructs the first sulfonation step of the bisulfite methylation reaction
protecting the cytosine nucleotide from conversion. b The sodium
bisulfite chemical reaction converts the unmethylated cytosines* at
position − 69 (from the Transcription Start Site) of insulin gene into
uracil which is replaced by a thymine nucleotide during the PCR
reaction, whereas methylated cytosines in other non-insulin DNA
sequence remain as cytosine. *The methylation occurs in CpG
dinucleotide (bold) in the human genome
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immediately post-infusion (within 1 h). This instant signal is
thought to be caused by cell hypoxia and the innate inflam-
matory responses. The second elevated signal is less intense
and more informative, observed 24 h post the infusion. This
latter signal was suggested by the authors to be a predictor of
islet engraft rejection as a higher level of hypomethylated INS
signal was linked to unfavourable graft outcomes [75••]. The
level of beta cell-specific INS cfDNAwas also studied in pa-
tients undergoing TPIAT. A study by Herold and colleagues
[69, 74••] showed that the relative level of hypomethylated
INS cfDNA was significantly raised in the first 3 h post-islet
infusion in TPIAT patients. Variable late beta cell-specific
signals were observed among the recipients, as well over the
following 30 days post the infusion suggesting inconsistency
in graft loss [74••]. They also reported that 30% of recipients
showed a high signal on day 90 post the infusion, which was
suggested by the authors to be associated with unfavourable
graft outcomes. The use of cfDNA as biomarkers (increasing-
ly advanced in the cancer field) are in their infancy in diabetes
research. Improved standardised beta cell-specific assays are
required to truly define their future clinical usefulness.
Conclusion
Islet transplantation has been shown to be a promising thera-
peutic approach that enhances the quality of life of patients
with T1D. The lack of accurate and efficient biomarkers to
monitor beta-cell death and predict engraftment function and
transplantation rejection still poses an immense challenge. In
recent years, biomarkers such as circulating miRNA-375 and
differentially methylated insulin cfDNA have emerged as po-
tentially powerful tools to detect real-time beta cell injury post
islet transplantation. A significant advantage of these bio-
markers is that they provide a real-time rate of beta-cell death
during and immediately after the islet infusion. Unlike meta-
bolic biomarkers, differentially methylated biomarkers and
microRNAs level are not affected by external physiological
changes or internal metabolic alteration. Nonetheless, the
identification of a panel of accurate, reliable and robust beta
cell-specific biomarkers is still in its infancy. Full validation of
these biomarkers is required in clinical islet transplantation
trials.
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